Ensuring a Consistent Supply of Anthrax Vaccine

DSpace/Manakin Repository

dc.contributor.advisor	Hutt, Peter Barton	en_US
dc.contributor.author	Gelfand, Rebecca A.	en_US
dc.date.accessioned	2012-06-07T20:11:22Z
dc.date.issued	2002	en_US
dc.identifier.citation	Ensuring a Consistent Supply of Anthrax Vaccine (2002 Third Year Paper)	en
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852116
dc.description.abstract	During the recent anthrax attacks, the country's supply of anthrax vaccine was dangerously low. The reasons for this were (1) the failure of the FDA, the Defense Department, and its contractor, BioPort Corporation, to plan adequately to ensure the production of a consistent supply of the vaccine in accordance with the FDA regulatory process; and (2) the reliance of the Defense Department on a single private supplier of the vaccine with serious financial problems. Careful planning should be employed to prevent such a situation with other biological products which may be needed to save lives during bioterrorist attacks.	en
dc.language.iso	en_US	en
dash.license	LAA	en_US
dc.subject	Food and Drug Law	en
dc.subject	vaccine,	en
dc.subject	anthrax,	en
dc.subject	FDA,	en
dc.subject	defense,	en
dc.subject	biologics	en
dc.title	Ensuring a Consistent Supply of Anthrax Vaccine	en
dc.type	Paper (for course/seminar/workshop)	en_US
dc.date.available	2012-06-07T20:11:22Z